A Phase 1 interventional study of Romosozumab in Osteoporosis, sponsored by Amgen. Completed at 5 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-22.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing romosozumab in Osteoporosis — 5 open to participants now, 8 under way, none of them phase 3. romosozumab · Osteoporosis.
Among the 20 studies testing romosozumab in Osteoporosis, this one is the 18th largest by enrollment, is the only one that started in 2013, is one of 3 in phase 1, and was the 4th registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →5 of the 20 studies testing romosozumab in Osteoporosis are open now, in 5 countries. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 50–80 · Women only
University of Aarhus · Sites in Denmark
Ages 50+ · Women only
Sahlgrenska University Hospital · Sites in Sweden
Ages 60+ · Women only
Tuen Mun Hospital · Sites in Hong Kong
Ages 18+
Marmara University · Sites in Turkey
Ages 55–85 · Women only
By country, each count listing its studies:
romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2013.
This study's enrollment of 24 is below the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 80 across the 20 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 20 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
34 studies in Osteoporosis by Amgen: none open now, 2 under way, none of them phase 3. Of 32 finished, 31 (97%) have results posted.
Among the 34 studies in Osteoporosis by Amgen, this one is the 28th largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2013, is one of 5 in phase 1, and was the 22nd registered.
Amgen’s Osteoporosis studies by the year they started, since 2002.
3 of the studies testing romosozumab in Osteoporosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05775094Memorial Sloan Kettering Cancer CenterA Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis | 2027-03 |
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
| NCT07757373Tuen Mun HospitalRomosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 Years | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies testing romosozumab in Osteoporosis, from their registry updates:
Among Amgen’s 34 in Osteoporosis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity profile of romosozumab after a single 210 mg subcutaneous dose in healthy participants and patients with stage 4 renal impairment (RI) or stage 5 RI requiring hemodialysis.
INCLUSION CRITERIA - ALL SUBJECTS :
INCLUSION CRITERIA - SUBJECTS WITH RENAL IMPAIRMENT (GROUPS 1 AND 2):
INCLUSION CRITERIA - HEALTHY SUBJECTS (GROUP 3):
EXCLUSION CRITERIA - ALL SUBJECTS:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with stage 4 renal impairment (defined as an estimated glomerular filtration rate \[eGFR\] 15 to 29 mL/min/1.73 m²) received a single subcutaneous injection of 210 mg romosozumab on day 1.
Drug: Romosozumab
Participants with end stage renal disease (ESRD) requiring hemodialysis received a single subcutaneous injection of 210 mg romosozumab on day 1.
Drug: Romosozumab
Healthy participants (eGFR ≥ 80 mL/min/1.73 m²) received a single subcutaneous injection of 210 mg romosozumab on day 1.
Drug: Romosozumab
Administered as three 70 mg/mL prefilled syringe injections
Also known as: AMG 785, EVENITY™
Number of Participants With Adverse Events
A serious adverse event was defined as an adverse event (AE) that met at least 1 of the following serious criteria: * fatal * life-threatening * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event. A treatment-related adverse event (TRAE) was an AE assessed by the investigator as possibly related to the study drug, indicated by a "yes" response to the question: "Is there a reasonable possibility that the event may have been caused by the investigational product?"
Time frame: From the first dose of study drug up to day 85
Number of Participants Who Developed Anti-Romosozumab Antibodies
Two validated assays were used to detect the presence of anti-romosozumab antibodies. First, an electrochemiluminescent immunoassay was used to detect binding antibodies (screening assay) and confirm antibodies (confirmatory assay) capable of binding romosozumab. Second, a non-cell-based competitive binding bioassay was used to test positive binding antibody samples for neutralizing activity against romosozumab. If a sample was positive for binding antibodies and demonstrated neutralizing activity at the same time point, the participant was defined as positive for neutralizing antibodies.
Time frame: Baseline and day 85
Albumin-Adjusted Serum Calcium Concentrations by Visit
Albumin-adjusted calcium was derived as: Where serum albumin \< 40 g/L then albumin-adjusted calcium = measured total calcium (mmol/L) + 0.02 \* \[40 - serum albumin (g/L)\]; Where serum albumin ≥ 40 g/L then albumin-adjusted calcium = measured total calcium.
Time frame: Baseline, days 8, 15, 22, 29, 43, 57, and 85/end of study visit
Intact Parathyroid Hormone (iPTH)Concentrations by Visit
Time frame: Baseline, days 8, 15, 22, 29, 43, 57, and 85/end of study visit
Maximum Observed Serum Concentration (Cmax) of Romosozumab
Time frame: Pre-dose on day -1 and on days 2, 3, 4, 6, 8, 11, 15, 18, 22, 29, 36, 43, 57 and 85
Time to Maximum Observed Serum Concentration (Tmax) of Romosozumab
Time frame: Pre-dose on day -1 and on days 2, 3, 4, 6, 8, 11, 15, 18, 22, 29, 36, 43, 57 and 85
Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)
Time frame: Pre-dose on day -1 and on days 2, 3, 4, 6, 8, 11, 15, 18, 22, 29, 36, 43, 57 and 85
Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)
Time frame: Pre-dose on day -1 and on days 2, 3, 4, 6, 8, 11, 15, 18, 22, 29, 36, 43, 57 and 85
This study was conducted at 5 centers in the United States. The first participant enrolled on 22 April 2013 and the last participant enrolled on 05 November 2013.
| Milestone | Group 1: Stage 4 Renal Impairment | Group 2: ESRD Requiring Hemodialysis | Group 3: Healthy Participants |
|---|---|---|---|
| Started | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 |
A serious adverse event was defined as an adverse event (AE) that met at least 1 of the following serious criteria: * fatal * life-threatening * required in-patient hospitalization or prolongation of existing hospitalization * resulted in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event. A treatment-related adverse event (TRAE) was an AE assessed by the investigator as possibly related to the study drug, indicated by a "yes" response to the question: "Is there a reasonable possibility that the event may have been caused by the investigational product?"
| Participants | Group 1: Stage 4 Renal Impairment | Group 2: ESRD Requiring Hemodialysis | Group 3: Healthy Participants |
|---|---|---|---|
| All adverse events | 7 | 6 | 0 |
| Serious adverse events | 1 | 1 | 0 |
| AEs leading to discontinuation of study drug | 0 | 0 | 0 |
| Fatal adverse events | 0 | 0 | 0 |
| Treatment-related adverse events | 5 | 6 | 0 |
| Treatment-related serious adverse events | 0 | 0 | 0 |
| TRAEs leading to discontinuation of study drug | 0 | 0 | 0 |
| Treatment-related fatal adverse events | 0 | 0 | 0 |
| µg/mL | Group 1: Stage 4 Renal Impairment | Group 2: ESRD Requiring Hemodialysis | Group 3: Healthy Participants |
|---|---|---|---|
| Maximum Observed Serum Concentration (Cmax) of Romosozumab | 28.9 ± 10.8 | 19.8 ± 7.3 | 22.4 ± 10.3 |
| days | Group 1: Stage 4 Renal Impairment | Group 2: ESRD Requiring Hemodialysis | Group 3: Healthy Participants |
|---|---|---|---|
| Time to Maximum Observed Serum Concentration (Tmax) of Romosozumab | 5.0 ± 10.8 | 5.0 ± 7.3 | 5.0 ± 10.3 |
| days*µg/mL | Group 1: Stage 4 Renal Impairment | Group 2: ESRD Requiring Hemodialysis | Group 3: Healthy Participants |
|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) | 637 ± 218 | 444 ± 154 | 443 ± 143 |
| days*µg/mL | Group 1: Stage 4 Renal Impairment | Group 2: ESRD Requiring Hemodialysis | Group 3: Healthy Participants |
|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) | 642 ± 221 | 447 ± 154 | 445 ± 143 |
Two validated assays were used to detect the presence of anti-romosozumab antibodies. First, an electrochemiluminescent immunoassay was used to detect binding antibodies (screening assay) and confirm antibodies (confirmatory assay) capable of binding romosozumab. Second, a non-cell-based competitive binding bioassay was used to test positive binding antibody samples for neutralizing activity against romosozumab. If a sample was positive for binding antibodies and demonstrated neutralizing activity at the same time point, the participant was defined as positive for neutralizing antibodies.
| Participants | Group 1: Stage 4 Renal Impairment | Group 2: ESRD Requiring Hemodialysis | Group 3: Healthy Participants |
|---|---|---|---|
| Binding antibody positive | 0 | 0 | 1 |
| Neutralizing antibody positive | 0 | 0 | 0 |
Albumin-adjusted calcium was derived as: Where serum albumin \< 40 g/L then albumin-adjusted calcium = measured total calcium (mmol/L) + 0.02 \* \[40 - serum albumin (g/L)\]; Where serum albumin ≥ 40 g/L then albumin-adjusted calcium = measured total calcium.
| mmol/L | Group 1: Stage 4 Renal Impairment | Group 2: ESRD Requiring Hemodialysis | Group 3: Healthy Participants |
|---|---|---|---|
| Baseline | 2.452 ± 0.228 | 2.379 ± 0.131 | 2.340 ± 0.057 |
| Day 8 | 2.355 ± 0.187 | 2.226 ± 0.205 | 2.308 ± 0.072 |
| Day 15 | 2.378 ± 0.146 | 2.194 ± 0.107 | 2.293 ± 0.070 |
| Day 22 | 2.329 ± 0.151 | 2.074 ± 0.193 | 2.311 ± 0.104 |
| Day 29 | 2.338 ± 0.162 | 2.166 ± 0.258 | 2.316 ± 0.062 |
| Day 43 | 2.404 ± 0.200 | 2.209 ± 0.169 | 2.320 ± 0.065 |
| Day 57 | 2.406 ± 0.179 | 2.284 ± 0.114 | 2.319 ± 0.070 |
| End of Study | 2.428 ± 0.201 | 2.291 ± 0.264 | 2.330 ± 0.065 |
| pmol/L | Group 1: Stage 4 Renal Impairment | Group 2: ESRD Requiring Hemodialysis | Group 3: Healthy Participants |
|---|---|---|---|
| Baseline | 5.014 ± 1.597 | 11.765 ± 12.003 | 4.682 ± 3.432 |
| Day 8 | 9.192 ± 3.077 | 19.812 ± 16.289 | 6.776 ± 3.612 |
| Day 15 | 8.887 ± 4.743 | 17.376 ± 10.108 | 6.473 ± 3.880 |
| Day 22 | 10.425 ± 4.190 | 29.724 ± 20.565 | 6.818 ± 3.959 |
| Day 29 | 12.495 ± 5.248 | 29.857 ± 20.461 | 7.348 ± 3.997 |
| Day 43 | 9.921 ± 5.906 | 21.374 ± 14.184 | 6.508 ± 3.289 |
| Day 57 | 9.311 ± 4.571 | 17.893 ± 11.196 | 5.279 ± 2.215 |
| End of Study | 6.958 ± 3.812 | 23.503 ± 24.339 | 4.457 ± 2.506 |
Collected over From the first dose of study drug up to day 85.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Stage 4 Renal Impairment | — | 1/8 (12.5%) | 7/8 (87.5%) |
| Group 2: ESRD Requiring Hemodialysis | — | 1/8 (12.5%) | 6/8 (75%) |
| Group 3: Healthy Participants | — | 0/8 (0%) | 0/8 (0%) |
| Event | Group 1: Stage 4 Renal Impairment | Group 2: ESRD Requiring Hemodialysis | Group 3: Healthy Participants |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/8 | 0/8 | 0/8 |
| Mitral valve diseaseCardiac disorders | 0/8 | 1/8 | 0/8 |
| Event | Group 1: Stage 4 Renal Impairment | Group 2: ESRD Requiring Hemodialysis | Group 3: Healthy Participants |
|---|---|---|---|
| Hyperparathyroidism secondaryEndocrine disorders | 4/8 | 0/8 | 0/8 |
| HypocalcaemiaMetabolism and nutrition disorders | 1/8 | 4/8 | 0/8 |
| ConstipationGastrointestinal disorders | 0/8 | 2/8 | 0/8 |
| Atrial fibrillationCardiac disorders | 0/8 | 1/8 | 0/8 |
| HyperparathyroidismEndocrine disorders | 1/8 | 0/8 | 0/8 |
| Abdominal discomfortGastrointestinal disorders | 0/8 | 1/8 | 0/8 |
| GastritisGastrointestinal disorders | 1/8 | 0/8 | 0/8 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/8 | 0/8 | 0/8 |
| Gingival recessionGastrointestinal disorders | 1/8 | 0/8 | 0/8 |
| HaemorrhoidsGastrointestinal disorders | 1/8 | 0/8 | 0/8 |
| Age, Continuous(years) | Group 1: Stage 4 Renal Impairment | Group 2: ESRD Requiring Hemodialysis | Group 3: Healthy Participants | Total |
|---|---|---|---|---|
| Mean | 66.5 ± 8.4 | 65.1 ± 6.7 | 63.0 ± 8.8 | 64.9 ± 7.8 |
| Sex: Female, Male(Participants) | Group 1: Stage 4 Renal Impairment | Group 2: ESRD Requiring Hemodialysis | Group 3: Healthy Participants | Total |
|---|---|---|---|---|
| Female | 4 | 3 | 7 | 14 |
| Male | 4 | 5 | 1 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: Stage 4 Renal Impairment | Group 2: ESRD Requiring Hemodialysis | Group 3: Healthy Participants | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 2 | 10 |
| Not Hispanic or Latino | 4 | 4 | 6 | 14 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Group 1: Stage 4 Renal Impairment | Group 2: ESRD Requiring Hemodialysis | Group 3: Healthy Participants | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Black or African American | 1 | 3 | 1 | 5 |
| White | 6 | 5 | 7 | 18 |
Ran from Apr 2013 to primary completion in Feb 2014, 9 months.
Results were first posted in Feb 2019, 5 years after primary completion.
Of 30 phase 1 interventional studies under Osteoporosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 22. This study's 9 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romosozumab